Themis, a Vienna, Austria-based developer of vaccines, closed a €10m Series C financing round.
The round was led by Global Health Investment Fund (GHIF), with participation from current investors aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences. In conjunction with the funding, Glenn Rockman, Partner at GHIF, will join Themis’ Supervisory Board.
The company intends to use the funds to advance clinical and pre-clinical vaccine development programs, including its most advanced vaccine against chikungunya virus, on which it recently reported positive Phase 2 results.
Led by Dr. Erich Tauber, CEO and founder, Themis is developing vaccines to prevent death and disability around the world. The company is advancing a vaccine against chikungunya virus, a mosquito-transmitted disease that can have debilitating long-term effects. The disease causes fever, joint pain and muscle pain, among other symptoms, and has no current treatment or prevention options. Its chikungunya vaccine is in Phase 2 clinical studies in 600 patients across the US, EU and South and Central America. The company is also developing vaccines against Zika virus, respiratory syncytial virus (RSV), norovirus and cytomegalovirus (CMV), as well as other applications of immune system activation.